keyword
MENU ▼
Read by QxMD icon Read
search

Cardiovascular outcome trials

keyword
https://www.readbyqxmd.com/read/27932413/biomarkers-and-coronary-lesions-predict-outcomes-after-revascularization-in-non-st-elevation-acute-coronary-syndrome
#1
Daniel Lindholm, Stefan K James, Maria Bertilsson, Richard C Becker, Christopher P Cannon, Evangelos Giannitsis, Robert A Harrington, Anders Himmelmann, Frederic Kontny, Agneta Siegbahn, Philippe Gabriel Steg, Robert F Storey, Matthijs A Velders, W Douglas Weaver, Lars Wallentin
BACKGROUND: Risk stratification in non-ST-elevation acute coronary syndrome (NSTE-ACS) is currently mainly based on clinical characteristics. With routine invasive management, angiography findings and biomarkers are available and may improve prognostication. We aimed to assess if adding biomarkers [high-sensitivity cardiac troponin T (cTnT-hs), N-terminal probrain-type natriuretic peptide (NT-proBNP), growth differentiation factor 15 (GDF-15)] and extent of coronary artery disease (CAD) might improve prognostication in revascularized patients with NSTE-ACS...
December 8, 2016: Clinical Chemistry
https://www.readbyqxmd.com/read/27932353/ezetimibe-in-combination-with-statins-ameliorates-endothelial-dysfunction-in-coronary-arteries-after-stenting-the-cuvic-trial-effect-of-cholesterol-absorption-inhibitor-usage-on-target-vessel-dysfunction-after-coronary-stenting-a-multicenter-randomized-controlled
#2
Susumu Takase, Tetsuya Matoba, Soichi Nakashiro, Yasushi Mukai, Shujiro Inoue, Keiji Oi, Taiki Higo, Shunsuke Katsuki, Masao Takemoto, Nobuhiro Suematsu, Kenichi Eshima, Kenji Miyata, Mitsutaka Yamamoto, Makoto Usui, Kenji Sadamatsu, Shinji Satoh, Toshiaki Kadokami, Kiyoshi Hironaga, Ikuyo Ichi, Koji Todaka, Junji Kishimoto, Kensuke Egashira, Kenji Sunagawa
OBJECTIVES: We sought to investigate whether treatment with ezetimibe in combination with statins improves coronary endothelial function in target vessels in coronary artery disease patients after coronary stenting. APPROACH AND RESULTS: We conducted a multicenter, prospective, randomized, open-label, blinded-end point trial among 11 cardiovascular treatment centers. From 2011 to 2013, 260 coronary artery disease patients who underwent coronary stenting were randomly allocated to 2 arms (statin monotherapy (S) versus ezetimibe [10 mg/d]+statin combinational therapy [E+S])...
December 8, 2016: Arteriosclerosis, Thrombosis, and Vascular Biology
https://www.readbyqxmd.com/read/27930863/lessons-from-a-cardiovascular-outcome-trial-with-liraglutide-in-type-2-diabetes
#3
Hae Jin Kim, Dae Jung Kim
Cardiovascular disease (CVD) is the leading cause of death and one of common diabetes-related complications in patients with type 2 diabetes(1) . After the US Food and Drug Administration issued guidelines for assessing the CVD risk of all new glucose-lowering agents for type 2 diabetes in 2008(2) , randomized controlled CV outcome trials with new antidiabetic drugs, such as the dipeptidyl peptidase-4 inhibitors (saxagliptin, alogliptin, and sitagliptin) and the glucagon-like peptide-1 receptor agonist (GLP-1 RA), lixisenatide, showed CV safety in high CV risk patient populations with type 2 diabtes(3) ...
December 8, 2016: Journal of Diabetes Investigation
https://www.readbyqxmd.com/read/27928947/oral-glucose-lowering-drugs-and-cardiovascular-outcomes-from-the-negative-record-and-accord-to-neutral-tecos-and-promising-empa-reg
#4
C Tsioufis, E Andrikou, C Thomopoulos, N Papanas, D Tousoulis
Cardiovascular (CV) morbidity and mortality are higher among patients with diabetes mellitus type 2 (T2DM), particularly those with concomitant CV diseases, compared with other populations. In patients with T2DM, intensive glucose lowering reduces microvascular disease, but has a smaller and debated effect on CV events or mortality. In this setting, the US Food and Drug Administration (FDA) required in 2008 that all new agents for the treatment of T2DM should be evaluated in terms of CV safety. Metformin has long been established as first-line pharmacological therapy in patients with T2DM, due to its proven beneficial CV effects...
December 8, 2016: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/27928711/dry-weight-assessment-by-combined-ultrasound-and-bioimpedance-monitoring-in-low-cardiovascular-risk-hemodialysis-patients-a-randomized-controlled-trial
#5
Dimitrie Siriopol, Mihai Onofriescu, Luminita Voroneanu, Mugurel Apetrii, Ionut Nistor, Simona Hogas, Mehmet Kanbay, Radu Sascau, Dragos Scripcariu, Adrian Covic
PURPOSE: Fluid overload is associated with adverse outcomes in hemodialysis (HD) patients. The precise assessment of hydration status in HD patients remains a major challenge for nephrologists. Our study aimed to explore whether combining two bedside methods, lung ultrasonography (LUS) and bioimpedance, may provide complementary information to guide treatment in specific HD patients. METHODS: In total, 250 HD patients from two dialysis units were included in this randomized clinical trial...
December 7, 2016: International Urology and Nephrology
https://www.readbyqxmd.com/read/27927621/optimism-and-cause-specific-mortality-a-prospective-cohort-study
#6
Eric S Kim, Kaitlin A Hagan, Francine Grodstein, Dawn L DeMeo, Immaculata De Vivo, Laura D Kubzansky
Growing evidence has linked positive psychological attributes like optimism to a lower risk of poor health outcomes, especially cardiovascular disease. It has been demonstrated in randomized trials that optimism can be learned. If associations between optimism and broader health outcomes are established, it may lead to novel interventions that improve public health and longevity. In the present study, we evaluated the association between optimism and cause-specific mortality in women after considering the role of potential confounding (sociodemographic characteristics, depression) and intermediary (health behaviors, health conditions) variables...
December 7, 2016: American Journal of Epidemiology
https://www.readbyqxmd.com/read/27927602/acute-change-in-glomerular-filtration-rate-with%C3%A2-inhibition-of-the-renin-angiotensin-system-does-not%C3%A2-predict-subsequent-renal-and-cardiovascular%C3%A2-outcomes
#7
Catherine M Clase, Joshua Barzilay, Peggy Gao, Andrew Smyth, Roland E Schmieder, Sheldon Tobe, Koon K Teo, Salim Yusuf, Johannes F E Mann
Initiation of blockade of the renin-angiotensin system may cause an acute decrease in glomerular filtration rate (GFR): the prognostic significance of this is unknown. We did a post hoc analysis of patients with, or at risk for, vascular disease, in two randomized controlled trials: Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) and the Telmisartan Randomized AssessmeNt Study in ACE iNtolerant participants with cardiovascular Disease (TRANSCEND), whose median follow-up was 56 months...
December 4, 2016: Kidney International
https://www.readbyqxmd.com/read/27927588/effect-of-coenzyme-q10-on-biomarkers-of-oxidative-stress-and%C3%A2-cardiac-function-in-hemodialysis-patients-the-coq10-biomarker-trial
#8
Matthew B Rivara, Catherine K Yeung, Cassianne Robinson-Cohen, Brian R Phillips, John Ruzinski, Denise Rock, Lori Linke, Danny D Shen, T Alp Ikizler, Jonathan Himmelfarb
BACKGROUND: Oxidative stress is highly prevalent in patients with end-stage renal disease and is linked to excess cardiovascular risk. Identifying therapies that reduce oxidative stress has the potential to improve cardiovascular outcomes in patients undergoing maintenance dialysis. STUDY DESIGN: Placebo-controlled, 3-arm, double-blind, randomized, clinical trial. SETTING & PARTICIPANTS: 65 patients undergoing thrice-weekly maintenance hemodialysis...
December 4, 2016: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/27927063/inflammation-and-beyond-new-directions-and-emerging-drugs-for-treating-atherosclerosis
#9
Marie-Jeanne Bertrand, Jean-Claude Tardif
Cardiovascular (CV) atherosclerotic disease remains the leading cause of morbidity and mortality worldwide, despite the advances in contemporary therapies. Inflammation is an important process in atherosclerosis, leading to plaque rupture and acute coronary syndrome. Although statin therapy has substantially reduced CV events in primary and secondary prevention, many treated patients will have recurrent adverse CV events despite the standard of care. Thus, drug development aiming to target inflammatory pathways seems a promising avenue for novel therapies in atherosclerosis...
December 7, 2016: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/27926769/myocardial-fibrosis-progression-in-duchenne-and-becker-muscular-dystrophy-a-randomized-clinical-trial
#10
Marly Conceição Silva, Tiago Augusto Magalhães, Zilda Maria Alves Meira, Carlos Henrique Reis Esselin Rassi, Amanda Cristina de Souza Andrade, Paulo Sampaio Gutierrez, Clerio Francisco Azevedo, Juliana Gurgel-Giannetti, Mariz Vainzof, Mayana Zatz, Roberto Kalil-Filho, Carlos Eduardo Rochitte
Importance: In Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), interventions reducing the progression of myocardial disease could affect survival. Objective: To assess the effect of early angiotensin-converting enzyme (ACE) inhibitor therapy in patients with normal left ventricular function on the progression of myocardial fibrosis (MF) identified on cardiovascular magnetic resonance (CMR). Design, Setting, and Participants: A randomized clinical trial conducted in 2 centers included 76 male patients with DMD or BMD undergoing 2 CMR studies with a 2-year interval for ventricular function and MF assessment...
December 7, 2016: JAMA Cardiology
https://www.readbyqxmd.com/read/27926633/effects-of-calcium-vitamin-d-and-hormone-therapy-on-cardiovascular-disease-risk-factors-in-the-women-s-health-initiative-a-randomized-controlled-trial
#11
Peter F Schnatz, Xuezhi Jiang, Aaron K Aragaki, Matthew Nudy, David M OʼSullivan, Mark Williams, Erin S LeBlanc, Lisa W Martin, JoAnn E Manson, James M Shikany, Karen C Johnson, Marcia L Stefanick, Martha E Payne, Jane A Cauley, Barbara V Howard, John Robbins
OBJECTIVE: To analyze the treatment effect of calcium+vitamin D supplementation, hormone therapy, both, and neither on cardiovascular disease risk factors. METHODS: We conducted a prospective, randomized, double-blind, placebo-controlled trial among Women's Health Initiative (WHI) participants. The predefined primary outcome was low-density lipoprotein cholesterol (LDL-C). RESULTS: Between September 1993 and October 1998, a total of 68,132 women aged 50-79 years were recruited and randomized to the WHI-Dietary Modification (n=48,835) and WHI-Hormone Therapy trials (n=27,347)...
December 2, 2016: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/27926497/coronary-computed-tomographic-angiography-for-patients-with-low-to-intermediate-risk-chest-pain-a-systematic-review-and-meta-analysis
#12
REVIEW
Yu Chen, Yuqi Fan, Zhaofang Yin, Huili Zhang, Yang Zhang, Zhihua Han, Changqian Wang
Coronary computed tomographic angiography (CCTA) can image the coronary vasculature rapidly and detect the presence and severity of luminal stenosis accurately. However, whether CCTA based care strategy could gain more benefits than conventional strategy with functional tests for patients with low-to-intermediate risk chest pain remains unknown. In this study we performed a meta-analysis to compare the clinical efficacy of CCTA versus conventional strategy. Eight randomized controlled trials with 14749 patients were finally included in this review after database searching...
December 2, 2016: Oncotarget
https://www.readbyqxmd.com/read/27924645/cardiovascular-outcomes-and-tumour-necrosis-factor-antagonists-in-chronic-inflammatory-rheumatic-disease-a-focus-on-rheumatoid-arthritis
#13
Giuliano Tocci, Delia Goletti, Valentina Marino, Andrea Matucci, Giuseppe Maria Milano, Fabrizio Cantini, Raffaele Scarpa
Many chronic rheumatic diseases have an inflammatory etiology, leading to accelerated atherosclerosis and increased occurrence of vascular diseases. In rheumatoid arthritis (RA), a reduction in cardiovascular (CV) events has been reported under treatments reducing systemic inflammation. Areas covered: Given the central role of tumour necrosis factor alpha (TNFα) in chronic inflammatory conditions and in atherosclerosis, it has been suggested that TNFα-antagonists may reduce CV risk and mortality. Although there are no randomized controlled or head-to-head trials investigating the effect of specific anti-TNF-agents on CV outcomes, observational cohort studies, national registry data, and meta-analyses in RA have reported improved CV outcomes with anti-TNF therapy...
December 2016: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/27924618/cardiovascular-disease-risk-factors-and-health-outcomes-among-american-indians-in-oklahoma-the-thrive-study
#14
Valarie Blue Bird Jernigan, Marianna Wetherill, Jordan Hearod, Tvli Jacob, Alicia L Salvatore, Tamela Cannady, Mandy Grammar, Joy Standridge, Jill Fox, Jennifer Spiegel, AnDina Wiley, Carolyn Noonan, Dedra Buchwald
INTRODUCTION: Limited available data document higher prevalences of cardiovascular disease (CVD) risk factors and health outcomes among American Indians (AIs) compared to other racial/ethnic groups. METHODS: As part of a randomized control trial to improve tribal food and physical activity environments, our tribal-academic partnership surveyed a cross-sectional sample of American Indian adults (n = 513) to assess the prevalence of type 2 diabetes, obesity, hypertension, tobacco use, physical activity, and vegetable and fruit intake...
December 6, 2016: Journal of Racial and Ethnic Health Disparities
https://www.readbyqxmd.com/read/27920083/nocturnal-antihypertensive-treatment-in-patients-with-type-1-diabetes-with-autonomic-neuropathy-and-non-dipping-a-randomised-placebo-controlled-double-blind-cross-over-trial
#15
Henrik Øder Hjortkjær, Tonny Jensen, Klaus F Kofoed, Ulrik M Mogensen, Per Ejlstrup Sigvardsen, Lars Køber, Karen Lisa Hilsted, Helle Corinth, Simone Theilade, Jannik Hilsted
OBJECTIVES: Cardiovascular autonomic neuropathy (CAN) and abnormal circadian blood pressure (BP) rhythm are independent cardiovascular risk factors in patients with diabetes and associations between CAN, non-dipping of nocturnal BP and coronary artery disease have been demonstrated. We aimed to test if bedtime dosing (BD) versus morning dosing (MD) of the ACE inhibitor enalapril would affect the 24-hour BP profile in patients with type 1 diabetes (T1D), CAN and non-dipping. SETTING: Secondary healthcare unit in Copenhagen, Denmark...
December 5, 2016: BMJ Open
https://www.readbyqxmd.com/read/27919826/should-blood-pressure-goal-be-individualized-in-hypertensive-patients
#16
REVIEW
Alexandra Yannoutsos, Rania Kheder-Elfekih, Jean-Michel Halimi, Michel E Safar, Jacques Blacher
The aim of the present review is to consider the clinical relevance of individualized blood pressure (BP) goal under treatment in hypertensive patients according to their age, comorbidities or established cardiovascular (CV) disease. Evidence from large-scale randomized trials to support a lower BP goal, as initially recommended by guidelines in high-risk hypertensive patients, were lacking. Recently, the randomized intervention SPRINT trial studied two treatment targets for systolic BP (120mm Hg versus 140mm Hg in the intensive and standard treatment group, respectively) among high-risk hypertensive patients, without diabetes and without a history of prior stroke...
December 2, 2016: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/27916514/dipeptidyl-peptidase-4-inhibitors-and-protection-against-stroke-a-systematic-review-and-meta-analysis
#17
REVIEW
F Barkas, M Elisaf, V Tsimihodimos, H Milionis
BACKGROUND: Type 2 diabetes mellitus (T2DM) is associated with an increased risk of stroke and an unfavourable outcome following stroke. Apart from pioglitazone, glucose-lowering modalities have not been shown to protect against stroke. Nevertheless, there is evidence from experimental studies of potential neuroprotective effects with dipeptidyl peptidase (DPP)-4 inhibitors, especially if treatment starts before stroke. OBJECTIVE: To perform a meta-analysis of available evidence regarding the risk of stroke in individuals taking DPP-4 inhibitors...
December 1, 2016: Diabetes & Metabolism
https://www.readbyqxmd.com/read/27914504/on-treatment-analysis-of-the-improved-reduction-of-outcomes-vytorin-efficacy-international-trial-improve-it
#18
Michael A Blazing, Robert P Giugliano, James A de Lemos, Christopher P Cannon, Andrew Tonkin, Christie M Ballantyne, Basil S Lewis, Thomas A Musliner, Andrew M Tershakovec, Yuliya Lokhnygina, Jennifer A White, Craig Reist, Amy McCagg, Eugene Braunwald
BACKGROUND: We aimed to determine the efficacy and safety of adding ezetimibe (Ez) to simvastatin (S) in a post-acute coronary syndrome (ACS) population in a prespecified on-treatment analysis. METHODS: We evaluated 17,706 post-ACS patients from the IMPROVE-IT trial who had low-density lipoprotein cholesterol values between 50 and 125 mg/dL and who received Ez 10 mg/d with S 40 mg/d (Ez/S) or placebo with simvastatin 40 mg/d (P/S). The primary composite end point was cardiovascular death, myocardial infarction, unstable angina, coronary revascularization ≥30 days postrandomization, or stroke...
December 2016: American Heart Journal
https://www.readbyqxmd.com/read/27912941/effects-of-dance-interventions-on-cardiovascular-risk-with-ageing-systematic-review-and-meta-analysis
#19
REVIEW
Josianne Rodrigues-Krause, Juliano Boufleur Farinha, Mauricio Krause, Álvaro Reischak-Oliveira
BACKGROUND: Exercising, including dancing, has been recommended to improve cardiovascular health of older people. Herein, we conducted a systematic review and meta-analysis verifying the effects of dance interventions on cardiovascular risk (CVR) in the elderly, comparing dancers to non-exercise controls and other types of exercise, in randomised (RCTs) and non-randomised control trials (nRCTs). Primary/Secondary outcomes: peak oxygen consumption (VO2peak)/anthropometric measurements (body weight, BMI), and lipid profile...
December 2016: Complementary Therapies in Medicine
https://www.readbyqxmd.com/read/27912776/improving-stroke-prevention-therapy-for-patients-with-atrial-fibrillation-in-primary-care-protocol-for-a-pragmatic-cluster-randomized-trial
#20
Theresa M Lee, Noah M Ivers, Sacha Bhatia, Debra A Butt, Paul Dorian, Liisa Jaakkimainen, Kori Leblanc, Dan Legge, Dante Morra, Alissia Valentinis, Laura Wing, Jacqueline Young, Karen Tu
BACKGROUND: The prevalence of atrial fibrillation (AF) is growing as the population ages, and at least 15% of ischemic strokes are attributed to AF. However, many high-risk AF patients are not offered guideline-recommended stroke prevention therapy due to a variety of system, provider, and patient-level barriers. METHODS: We will conduct a pragmatic, cluster-randomized controlled trial randomizing primary care clinics to test a "toolkit" of quality improvement interventions in primary care...
December 3, 2016: Implementation Science: IS
keyword
keyword
119128
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"